Background and Aims

In normal physiology, insulin is secreted very rapidly from the β‐cell in response to, and even in anticipation of a meal. Despite advances in insulin formulations, subcutaneously administered insulins have a delayed onset and a longer duration of action compared with endogenously secreted insulin. This fact makes it challenging for persons with diabetes to control their postprandial glucose after most meals, whether patients are treated with basal-bolus insulin, insulin pumps or closed loop systems.

Rapid‐acting insulin analogues — insulin aspart, insulin lispro and insulin glulisine — have faster absorption kinetics than regular human insulin and are in the western world the most common fast-acting insulin used. However, the problem with postprandial hyperglycemia remains a major problem.

Fast‐acting insulin aspart (FiAsp) is a formulation of insulin aspart with an improved pharmacological profile and greater early glucose‐lowering action compared with insulin aspart, thus having the potential to be advantageous in controlling the glucose.

Methods

Review of publiced clinical trials with FiAsp

Results

Efficacy of FiAsp compared to other rapid acting insulin analogs used in MDI, insulin pumps and closed loop systems will be presented together with clinical experience using FiAsp.

Conclusions

Based on the data presented, the need for further studies to maximize the potential of FiAsp will be discussed